What Pfizer's Quarter ended Sep 27, 2026 10-Q says: 4 signals
Pfizer filed its latest 10-Q with the SEC on Nov 3, 2026. It discusses bookings decline, compliance burden and cost reduction.
Public (PFE)Pharmaceutical Manufacturing10,000+ employeespfizer.comLinkedIn
Get Pfizer's live signals in Claude or ChatGPT, or by API
What changed at Pfizer this week? Use Autobound signals for pfizer.com.- Filed
- Nov 3, 2026
- Period
- Quarter ended Sep 27, 2026
- Filings
- 3
- Signals
- 13
Source: Autobound Signal API · 104 signals tracked for Pfizer · updated
10-Q · latest 10
What Pfizer's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 27, 2026
Filed · 4 signals
Pfizer announced $1.0 billion in additional net cost savings from its Realigning Our Cost Base Program and $1.5 billion from its Manufacturing Optimization Program from 2027 through 2029.
Pfizer manages operations via two operating segments, Biopharma and PC1, beginning Q1 2026
Beginning in the first quarter of 2026, Pfizer manages commercial operations through a global structure consisting of two operating segments: Biopharma and PC1.
Paxlovid Q3 revenue drops 63% operationally to $449 million on lower COVID-19 infections
Pfizer reported a 63% operational decline in worldwide Paxlovid revenue to $449 million for the third quarter of 2026, driven by lower COVID-19 infection rates across the U.S.
-63%
Paxlovid QTD operational revenue decline
Pfizer reaches binding U.S. tariff agreement exempting patented pharmaceuticals through January 2029
Under agreements with the U.S. Government effective July 31, 2026, Section 232 tariffs on Pfizer's imported pharmaceuticals will remain at zero until January 20, 2029, in exchange for commitments to invest in U.S.
0%
applicable tariff rate under Section 232 Executive Order until January 20, 2029
- SEC EDGAR
10-Q · Quarter ended Jun 28, 2026
Filed · 4 signals
Pfizer announced $1.0 billion of additional net cost savings in its Realigning Our Cost Base Program and $1.5 billion in savings from its Manufacturing Optimization Program through 2029.
Pfizer commits $2 billion through 2029 for digital enablement and tech productivity enhancements
Pfizer announced $1.0 billion of additional anticipated net cost savings under its Realigning Our Cost Base Program driven by productivity enhancements from technology across commercial, R&D, and enabling functions.
$2B
one-time costs through 2029 for digital enablement, implementation and severance
digital enablement
Pfizer agreed to binding arrangements with the U.S.
0%
tariff rate applicable under Section 232 until January 20, 2029
- SEC EDGAR
10-Q · Quarter ended Mar 29, 2026
Filed · 5 signals
Realigning Our Cost Base program targets $5.7 billion total net cost savings through 2026
Pfizer expects its Realigning Our Cost Base Program to deliver total net cost savings of approximately $5.7 billion through 2026, including remaining anticipated savings of $600 million primarily in SI&A by end of 2026.
$5.7B
total net cost savings through 2026 under Realigning Our Cost Base Program
FDA Approved Veppanu (vepdegestrant) in May 2026 for Advanced or Metastatic Breast Cancer
Pfizer received U.S. FDA approval in May 2026 for Veppanu for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
Pfizer reorganized commercial operations into Biopharma and PC1 segments starting Q1 2026
Pfizer began managing its commercial operations through a global structure consisting of two operating segments: Biopharma and PC1, with Biopharma as the reportable segment, and wound down Pfizer Ignite.
Showing 10 of 13 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Pfizer earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Cost programs delivering $7.2B savings plus $2.5B phasePfizer remains on track to deliver nearly all of the anticipated $7.2 billion in net cost savings by the end of 2026. Additionally, the company initiated the next phase of productivity programs targeting another $2.5 billion in net cost savings from 2027 through 2029. | |
| Upcoming loss of exclusivity headwinds across key portfoliosPfizer is managing major loss of exclusivity headwinds including Eliquis in international markets at the end of 2026, followed by Ibrance and Xtandi in the US. These upcoming LOEs are pressuring top-line revenue, keeping debt leverage elevated around 2.6x to 2.7x, and forcing portfolio mitigation. | |
| Advancing collaborative programs with Valneva, Astellas, RelayPfizer is co-developing and advancing key late-stage candidates alongside strategic partners. These include an ongoing Lyme disease vaccine candidate with Valneva submitted for EMA review, Xtandi commercialization with Astellas, and clinical oncology combinations with Relay Therapeutics. | |
| Cecile Guegan appointed as new Chief Financial OfficerPfizer appointed Cecile Guegan as its new Chief Financial Officer, succeeding the previous CFO. Leadership changes in the finance seat often trigger re-evaluations of ongoing capital allocation, vendor contracts, and enterprise software systems. | |
| Deploying AI and Genesis across manufacturing and R&DPfizer has deployed AI across its enterprise to enhance manufacturing efficiency, physician/patient engagement, and drug discovery target validation. The company also launched its Genesis platform across 120 countries to automate administrative tasks for safety scientists. | |
| Managing pricing pressures from IRA, 340B, and MFNManagement highlighted pricing headwinds stemming from U.S. healthcare policy reform, including Inflation Reduction Act provisions, 340B program dynamics, and Most Favored Nation pricing rules. These regulatory pressures are factored directly into 2027 pricing expectations and net revenue realizations. |
Signal API · MCP
Track Pfizer with the Signal API
One POST /v1/companies/enrich call with pfizer.com returns Pfizer 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"pfizer.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Pfizer 10-Q
When did Pfizer file its latest 10-Q?
What did Pfizer disclose in its latest 10-Q?
What did Pfizer say on its recent earnings calls?
Where can I read Pfizer's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .